Stroke-Related RNA Biomarker Development Services

In animals, specific gene expression profiles are found in brain tissue and blood after ischemic stroke. There are differences in RNA gene expression in the blood of stroke patients. Similar to protein profiles associated with ischemic stroke, gene profiles expressed in ischemic stroke have been identified as markers. RNA as a biomarker has advantages over protein, because RNA expression can be measured at the level of the entire transcriptome, which provides different molecular information than protein-level analysis. In addition, non-coding RNA can also be used as a biomarker for stroke. RNA biomarkers are expected to help diagnose stroke, determine the cause of the disease, and provide new insights into the mechanisms of stroke in patients.

Fig. 1. LncRNAs as biomarkers of stroke. (Fan et al., 2020)

Our Services

Ace Therapeutics has years of experience in stroke biomarker development and offers comprehensive RNA biomarker screening, selection and validation services to accelerate your RNA biomarker program from early discovery to fully validated analysis.

A broad range of RNA biomarkers can be screened, and the relevant biomarkers can then be translated into focused panels and validated for your sample testing needs. Our team of experts is committed to assisting you with all your biomarker questions, and developing a customized approach to your RNA biomarker development program.

Types of Stroke-Related RNA Biomarkers We Can Develop

We perform gene expression analysis to quantify assess all genes expressed as RNA in cells, tissues or blood, helping our clients gain insight into the regulation of gene expression in stroke. Our scientists also use advanced gene chip technology to develop and validate a wide range of RNA biomarkers for pharmaceutical and biotechnology companies focused on stroke.

How to Develop Stroke-Related RNA Biomarkers

Discovery of Stroke-Related RNA Biomarkers

• We use standardized RNA extraction and purification methods to extract total RNA from animal derived materials include blood, cerebrospinal fluid, and tissue samples.
• We use high-throughput RNA sequencing technologies (e.g., RNA-seq) to sequence the extracted total RNA.
• We use bioinformatic analysis tools to compare the RNA expression profiles of stroke animals and healthy controls to identify differentially expressed RNA.

Selection and Evaluation of Stroke-Related RNA Biomarkers

• From the validated differentially expressed RNA molecules, we help our clients to select candidate biomarkers with high specificity and sensitivity for stroke.
• We provide in vitro and in vivo functional studies to help clients evaluate the potential of these candidates for stroke diagnosis and stroke prediction.

Detection of RNA Biomarkers in Stroke

We provide rapid, accurate, and cost-effective technologies to help clients detect RNA biomarkers in animal models of stroke.

• Individual cell types are isolated from blood using microfluidic sorting methods, and RNA in stroke is rapidly measured using methods such as high-throughput single-cell labeling.
• Rapid measurement of RNA using RT-PCR reactions on microarrays.
• Measurement of RNA using antibody–oligonucleotide conjugates.

With expertise in molecular biology and bioinformatics, Ace Therapeutics helps clients develop RNA biomarkers for stroke diagnosis and prediction of stroke cause. Please contact us for high-quality biomarker development services.

1. Fan, J., et al. (2020). LncRNAs stand as potent biomarkers and therapeutic targets for stroke. Frontiers in aging neuroscience, 12, 594571.